{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T00:31:10Z","timestamp":1794270670868,"version":"4.9.0"},"reference-count":63,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:00:00Z","timestamp":1767830400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>SMET12 is a bispecific T-cell engager targeting epidermal growth factor receptor (EGFR) and CD3. This phase 2 clinical trial aimed to investigate the efficacy and safety of SMET12 plus toripalimab and chemotherapy among advanced non-small-cell lung cancer (NSCLC) patients tested positive for EGFR protein, including treatment-na\u00efve patients, patients with resistance to first-line immune checkpoint inhibitors-containing therapy and EGFR-mutated patients with resistance to first-line EGFR tyrosine kinase inhibitors (TKIs), and to examine the associations of lymphocyte numbers and differentiation patterns with therapeutic efficacy among advanced NSCLC patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      All advanced NSCLC patients were histologically diagnosed and tested positive for EGFR protein. This trial included three cohorts: Cohort A consisted of treatment-na\u00efve patients, and Cohort B consisted of patients acquiring resistance to first-line immune checkpoint inhibitors-containing therapy, while Cohort C consisted of\n                      <jats:italic>EGFR<\/jats:italic>\n                      -mutated patients acquiring resistance to TKIs. All participants received triple therapy with SMET12, toripalimab and chemotherapy, and participants with complete response (CR), partial response (PR) or stable disease (SD) following 2 to 4 cycles of chemotherapy were given maintenance therapy with SMET12 plus toripalimab until progressive disease (PD) or unacceptable toxicity. Primary endpoints included safety and efficacy measures, including objective response rate (ORR), disease control rate (DCR), and progression-free survival (PFS). This trial was registered at\n                      <jats:ext-link>https:\/\/clinicaltrials.gov<\/jats:ext-link>\n                      (Trial registration number: NCT06208033).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 32 patients were included in the trial until January 21, 2025. The ORR, DCR and median PFS were 83.3%, 100% and 8.3 (95%\n                      <jats:italic>CI<\/jats:italic>\n                      : 3.8, 12.8) months in Cohort A, 22.2%, 55.6% and 4.2 (95%\n                      <jats:italic>CI<\/jats:italic>\n                      : 3.6, 4.8) months in Cohort B, and 41.7%, 100% and 7.2 (95%\n                      <jats:italic>CI<\/jats:italic>\n                      : 5.0, 9.4) months in Cohort C. The most common treatment-related adverse events (20% incidence and higher) included cytokine release syndrome (53.13%), leukopenia (43.75%), elevated alanine aminotransferase (43.75%), neutropenia (37.5%), constipation (31.25%), and elevated aspartate aminotransferase (28.13%). Grade 3\u20134 adverse events included neutropenia (15.63%), Lung infections (15.63%), anemia (6.25%), immune-related hepatitis (6.25%), immune-related pneumonia (6.25%), leukopenia (3.13%), and hypertriglyceridemia (3.13%). No grade 5 adverse events were observed. At baseline among the three cohorts, Cohort A presented the lowest Treg, PD-1\n                      <jats:sup>+<\/jats:sup>\n                      and LAG-3\n                      <jats:sup>+<\/jats:sup>\n                      T cell proportions; Cohort B had the highest Treg and LAG-3\n                      <jats:sup>+<\/jats:sup>\n                      T cell proportions, and Cohort C had the highest PD-1\n                      <jats:sup>+<\/jats:sup>\n                      T cell proportion. High numbers of peripheral blood T lymphocytes and CD69\n                      <jats:sup>+<\/jats:sup>\n                      T cells, and higher proportions of central memory T cells (Tcm) and na\u00efve T cells (Tn) may be predictive of a higher response to the triple therapy, and an increase in the positive rate of PD-1 and LAG3 expression on T cell surface and proportions of regulatory T cells (Tregs), effector memory T cells (Tem) and terminally differentiated effector T cells (Tte) may correlate with poor prognosis.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Triple therapy consisting of SMET12, toripalimab, and chemotherapy exhibited manageable safety in patients with advanced non-small cell lung cancer (NSCLC) expressing EGFR protein, while demonstrating promising efficacy in EGFR-mutant patients with acquired resistance to EGFR-TKIs. The functional phenotype and differentiation pattern of peripheral blood T lymphocytes exert a critical impact on the therapeutic response to this triple therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical trial registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/www.clinicaltrials.gov\/study\/<\/jats:ext-link>\n                      , identifier NCT06208033.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2025.1706961","type":"journal-article","created":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T06:36:41Z","timestamp":1767854201000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy and safety of SMET12 in combination with toripalimab and chemotherapy in advanced non-small-cell lung cancer patients tested positive for EGFR protein who are treatment-na\u00efve or harbor acquired resistance to standard therapy: a phase 2, multi-cohort clinical trial"],"prefix":"10.3389","volume":"16","author":[{"given":"Jinghui","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanshan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meifang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihong","family":"Weng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haipeng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haipo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinying","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyong","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00312-3","article-title":"Lung cancer","volume":"398","author":"Thai","year":"2021","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/s41572-024-00551-9","article-title":"Non-small-cell lung cancer","volume":"10","author":"Hendriks","year":"2024","journal-title":"Nat Rev Dis Prim"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-024-00914-x","article-title":"Emerging advances in defining the molecular and therapeutic landscape of small-cell lung cancer","volume":"21","author":"Sen","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s13045-025-01679-1","article-title":"Recent advances in therapeutic strategies for non-small cell lung cancer","volume":"18","author":"Su","year":"2025","journal-title":"J Hematol Oncol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s00408-025-00801-x","article-title":"Update 2025: Management of non\u2212small-cell lung cancer","volume":"203","author":"Jeon","year":"2025","journal-title":"Lung"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)01029-8","article-title":"New promises and challenges in the treatment of advanced non-small-cell lung cancer","volume":"404","author":"Meyer","year":"2024","journal-title":"Lancet"},{"key":"B7","author":"Orillard","year":""},{"key":"B8","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s12943-024-02212-7","article-title":"Resistance mechanisms to immune checkpoint inhibitors: updated insights","volume":"24","author":"Alsaafeen","year":"2025","journal-title":"Mol Can"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2025.101215","article-title":"Resistance to immunotherapy in non-small cell lung cancer: Unraveling causes, developing effective strategies, and exploring potential breakthroughs","volume":"81","author":"Dong","year":"2025","journal-title":"Drug Resist Updat"},{"key":"B10","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1097\/COC.0000000000001138","article-title":"Meta-analysis of targeted therapies in EGFR-mutated non-small cell lung cancer: Efficacy and safety of osimertinib, erlotinib, and gefitinib as first-line treatment","volume":"48","author":"Qureshi","year":"2025","journal-title":"Am J Clin Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15020504","article-title":"Mechanisms of acquired resistance and tolerance to EGFR targeted therapy in non-small cell lung cancer","volume":"15","author":"Chhouri","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3816\/CLC.2008.s.015","article-title":"New options for integrating antiangiogenic therapy and platinum-based first-line chemotherapy for advanced non-small-cell lung cancer","volume":"9","author":"Manegold","year":"2008","journal-title":"Clin Lung Can"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2022.078","article-title":"Challenges in the use of targeted therapies in non-small cell lung cancer","volume":"54","author":"Rivera-Concepcion","year":"2022","journal-title":"Cancer Res Treat"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2021.11.010","article-title":"Toward a better understanding of T cells in cancer","volume":"39","author":"Oh","year":"2021","journal-title":"Cancer Cell"},{"key":"B15","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s13073-018-0598-2","article-title":"Acquired mechanisms of immune escape in cancer following immunotherapy","volume":"10","author":"Iorgulescu","year":"2018","journal-title":"Genome Med"},{"key":"B16","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s40364-021-00294-9","article-title":"The landscape of bispecific T cell engager in cancer treatment","volume":"9","author":"Zhou","year":"2021","journal-title":"biomark Res"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-020-0347-5","article-title":"Bargou RC","volume":"17","author":"Goebeler","year":"2020","journal-title":"T cell-engaging therapies - BiTEs beyond Nat Rev Clin Oncol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/s41572-024-00542-w","article-title":"Tumour lysis syndrome","volume":"10","author":"Howard","year":"2024","journal-title":"Nat Rev Dis Prim"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.216726","article-title":"PD-1 regulation in immune homeostasis and immunotherapy","volume":"588","author":"Gao","year":"2024","journal-title":"Cancer Lett"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2023.01.041","article-title":"Microenvironment-responsive anti-PD-L1 \u00d7 CD3 bispecific T-cell engager for solid tumor immunotherapy","volume":"354","author":"Liu","year":"2023","journal-title":"J Control Rel"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13112748","article-title":"EGFR in cancer: Signaling mechanisms, drugs, and acquired resistance","volume":"13","author":"Uribe","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.3800939","article-title":"EGFR expression as an ancillary tool for diagnosing lung cancer in cytology specimens","volume":"20","author":"Wei","year":"2007","journal-title":"Mod Pathol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"48","DOI":"10.3978\/j.issn.2072-1439.2010.02.01.017","article-title":"Epidermal growth factor receptor (EGFR) in lung cancer: an overview and update","volume":"2","author":"Bethune","year":"2010","journal-title":"J Thorac Dis"},{"key":"B24","unstructured":""},{"key":"B25","unstructured":""},{"key":"B26","unstructured":""},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.730666","article-title":"Toripalimab: the first domestic anti-tumor PD-1 antibody in China","volume":"12","author":"Zhang","year":"2022","journal-title":"Front Immunol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.gendis.2022.02.007","article-title":"Cancer chemotherapy and beyond: Current status, drug candidates, associated risks and progress in targeted therapeutics","volume":"10","author":"Anand","year":"2022","journal-title":"Genes Dis"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2016.03.081","article-title":"RECIST 1.1-Update and clarification: From the RECIST committee","volume":"62","author":"Schwartz","year":"2016","journal-title":"Eur J Can"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1159\/000503095","article-title":"Performance status assessment by using ECOG (Eastern Cooperative Oncology Group) score for cancer patients by oncology healthcare professionals","volume":"12","author":"Azam","year":"2019","journal-title":"Case Rep Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30074-8","article-title":"iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics","volume":"18","author":"Seymour","year":"2017","journal-title":"Lancet Oncol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ad.2019.05.009","article-title":"Using the Common Terminology Criteria for Adverse Events (CTCAE - Version 5.0) to evaluate the severity of adverse events of anticancer therapies","volume":"112","author":"Freites-Martinez","year":"2021","journal-title":"Actas Dermosifiliogr (Engl Ed)"},{"key":"B33","doi-asserted-by":"publisher","first-page":"77","DOI":"10.20892\/j.issn.2095-3941.2024.0497","article-title":"Updates to the 2024 CSCO advanced non-small cell lung cancer guidelines","volume":"22","author":"Wang","year":"2025","journal-title":"Cancer Biol Med"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2020.07.014","article-title":"Efficacy and safety of sintilimab plus pemetrexed and platinum as first-line treatment for locally advanced or metastatic nonsquamous NSCLC: a randomized, double-blind, phase 3 study (Oncology pRogram by InnovENT anti-PD-1-11)","volume":"15","author":"Yang","year":"2020","journal-title":"J Thorac Oncol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(20)30365-9","article-title":"Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial","volume":"9","author":"Zhou","year":"2021","journal-title":"Lancet Respir Med"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.103727","article-title":"Tislelizumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced squamous non-small-cell lung cancer: final analysis of the randomized, phase III RATIONALE-307 trial","volume":"9","author":"Wang","year":"2024","journal-title":"ESMO Open"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00727","article-title":"Toripalimab plus chemotherapy for patients with treatment-naive advanced non-small-cell lung cancer: A multicenter randomized phase III trial (CHOICE-01)","volume":"41","author":"Wang","year":"2023","journal-title":"J Clin Oncol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1200\/JCO.22.01990","article-title":"Pembrolizumab plus chemotherapy in squamous non-small-cell lung cancer: 5-year update of the phase III KEYNOTE-407 study","volume":"41","author":"Novello","year":"2023","journal-title":"J Clin Oncol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01989","article-title":"Pembrolizumab plus pemetrexed and platinum in nonsquamous non-small-cell lung cancer: 5-year outcomes from the phase 3 KEYNOTE-189 study","volume":"41","author":"Garassino","year":"2023","journal-title":"J Clin Oncol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2021.0366","article-title":"Tislelizumab plus chemotherapy vs Chemotherapy alone as first-line treatment for advanced squamous non-small-cell lung cancer: A phase 3 randomized clinical trial","volume":"7","author":"Wang","year":"2021","journal-title":"JAMA Oncol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.04.011","article-title":"Sintilimab plus platinum and gemcitabine as first-line treatment for advanced or metastatic squamous NSCLC: Results from a randomized, double-blind, phase 3 trial (ORIENT-12)","volume":"16","author":"Zhou","year":"2021","journal-title":"J Thorac Oncol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.11.018","article-title":"Camrelizumab plus carboplatin and paclitaxel as first-line treatment for advanced squamous NSCLC (CameL-Sq): A phase 3 trial","volume":"17","author":"Ren","year":"2022","journal-title":"J Thorac Oncol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00650-1","article-title":"Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trial","volume":"23","author":"Zhou","year":"2022","journal-title":"Lancet Oncol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2023.100879","article-title":"Controversies in NSCLC: which second-line strategy after chemo-immunotherapy","volume":"8","author":"Moliner","year":"2023","journal-title":"ESMO Open"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.02744","article-title":"Therapy for stage IV non-small cell lung cancer without driver alterations: ASCO living guideline, version 2023.3","volume":"42","author":"Jaiyesimi","year":"2024","journal-title":"J Clin Oncol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy275","article-title":"Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Planchard","year":"2018","journal-title":"Ann Oncol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.34565","article-title":"A phase 2 trial of chemotherapy plus pembrolizumab in patients with advanced non-small cell lung cancer previously treated with a PD-1 or PD-L1 inhibitor: Big Ten Cancer Research Consortium BTCRC-LUN15-029","volume":"129","author":"Salous","year":"2023","journal-title":"Cancer"},{"key":"B48","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.annonc.2023.10.004","article-title":"SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"35","author":"Borghaei","year":"2024","journal-title":"Ann Oncol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1129465","article-title":"Immunotherapy resistance in non-small-cell lung cancer: From mechanism to clinical strategies","volume":"14","author":"Zhou","year":"2023","journal-title":"Front Immunol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"387","DOI":"10.3322\/caac.70024","article-title":"Personalized care for patients with EGFR-mutant nonsmall cell lung cancer: Navigating early to advanced disease management","volume":"75","author":"Borgeaud","year":"2025","journal-title":"CA Cancer J Clin"},{"key":"B51","doi-asserted-by":"publisher","first-page":"e008818","DOI":"10.1136\/jitc-2024-008818","article-title":"Immunotherapy-based regimens for patients with EGFR-mutated non-small cell lung cancer who progressed on EGFR-TKI therapy","volume":"12","author":"Qin","year":"2024","journal-title":"J Immunother Can"},{"key":"B52","doi-asserted-by":"publisher","first-page":"e247092","DOI":"10.6004\/jnccn.2024.7092","article-title":"Chemotherapy-based combination regimens for advanced EGFR-mutant NSCLC after EGFR-TKI failure: A network meta-analysis","volume":"23","author":"Pang","year":"2025","journal-title":"J Natl Compr Canc Netw"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.jncc.2024.06.004","article-title":"Immunological features of EGFR-mutant non-small cell lung cancer and clinical practice: a narrative review","volume":"4","author":"Dong","year":"2024","journal-title":"J Natl Cancer Cent"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanwpc.2024.101260","article-title":"Consensus on the lung cancer management after third-generation EGFR-TKI resistance","volume":"53","author":"Zhou","year":"2024","journal-title":"Lancet Reg Health West Pac"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2023.102602","article-title":"Immune checkpoint inhibitors in EGFR-mutant non-small cell lung cancer: A systematic review","volume":"119","author":"Attili","year":"2023","journal-title":"Cancer Treat Rev"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.02747","article-title":"Phase III KEYNOTE-789 study of pemetrexed and platinum with or without pembrolizumab for tyrosine kinase inhibitor-resistant, EGFR-mutant, metastatic nonsquamous non-small cell lung cancer","volume":"42","author":"Yang","year":"2024","journal-title":"J Clin Oncol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1038\/s41392-021-00751-9","article-title":"Toripalimab plus chemotherapy as second-line treatment in previously EGFR-TKI treated patients with EGFR-mutant-advanced NSCLC: a multicenter phase-II trial","volume":"6","author":"Jiang","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01017","article-title":"Nivolumab plus chemotherapy in epidermal growth factor receptor-mutated metastatic non-small-cell lung cancer after disease progression on epidermal growth factor receptor tyrosine kinase inhibitors: Final results of CheckMate 722","volume":"42","author":"Mok","year":"2024","journal-title":"J Clin Oncol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00382-5","article-title":"Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): first interim results from a randomised, double-blind, multicentre, phase 3 trial","volume":"23","author":"Lu","year":"2022","journal-title":"Lancet Oncol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.10613","article-title":"Ivonescimab plus chemotherapy in non-small cell lung cancer with EGFR variant: A randomized clinical trial","volume":"332","author":"Fang","year":"2024","journal-title":"JAMA"},{"key":"B61","doi-asserted-by":"publisher","first-page":"e004688","DOI":"10.1136\/jitc-2022-004688","article-title":"Peripheral blood immune cell dynamics reflect antitumor immune responses and predict clinical response to immunotherapy","volume":"10","author":"Hwang","year":"2022","journal-title":"J Immunother Can"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.912180","article-title":"Peripheral blood lymphocyte subsets predict the efficacy of immune checkpoint inhibitors in non-small cell lung cancer","volume":"13","author":"Miao","year":"2022","journal-title":"Front Immunol"},{"key":"B63","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s12885-023-10502-4","article-title":"Peripheral blood lymphocytes differentiation patterns in responses\/outcomes to immune checkpoint blockade therapies in non-small cell lung cancer: a retrospective study","volume":"23","author":"Du","year":"2023","journal-title":"BMC Can"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1706961\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T06:36:43Z","timestamp":1767854203000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1706961\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,8]]},"references-count":63,"alternative-id":["10.3389\/fimmu.2025.1706961"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1706961","relation":{"has-part":[{"id-type":"doi","id":"https:\/\/doi.org\/10.3389\/fimmu.2025.1706961.s001","asserted-by":"subject"}]},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,8]]},"article-number":"1706961"}}